DHRDanaher Corporation
- Next report
- No date yet
- none in the next 8 weeks
- Last result
- $2.11Beat
- vs $1.92 expected on Oct 21
- Stock move on it
- +2.46%
- two sessions around the report
- Typical move
- ±6.7%
- average over 2 reports
- Price
- $233.30
- −0.85% today · $135B cap
Past and upcoming reports
2
| Oct 21, 2026 | Sep 30, 2026 | Time not given | $1.92 | Beat$2.11 | +2.46%2d |
| Jul 21, 2026 | Jun 30, 2026 | Time not given | $1.83 | Beat$1.94 | −10.92%2d |
After the report
Jul 21, 2026 report
This covers the Jul 21, 2026 report. The Oct 21, 2026 numbers are in the table above.
Bioprocessing weakness overshadows earnings beat
Danaher reported Q2 EPS of $1.94, beating estimates by $0.10 (5.4%), but the stock edged down 0.52% as bioprocessing weakness persisted. Management commentary highlighted ongoing headwinds, keeping the near-term outlook cautious despite the beat.
Reported against expected
Danaher reported Q2 EPS of $1.94, beating the consensus estimate of $1.84 by $0.10 (5.4%).
Guidance
Guidance was not explicitly provided, but management commentary highlighted continued weakness in bioprocessing, suggesting a cautious near-term outlook.
How the stock reacted
The stock closed at $191.50 on Jul 22, down 0.52% from the previous close, reflecting market disappointment despite the EPS beat.
What changed
Q2 EPS beat by 5.4% but bioprocessing weakness clouded outlook, stock fell modestly.
What the price now assumes
Market is discounting near-term bioprocessing headwinds, evidenced by -0.52% post-release drift despite beat.
What it means for the business
Upgrade cautiously. monitor bioprocessing orders for stabilization before adding exposure.
The next one to three months, as we saw it then
Better case25%
Bioprocessing orders stabilize in Q3, driving revenue acceleration and multiple expansion.
Base case50%
Bioprocessing remains weak but other segments (life sciences, diagnostics) hold steady. stock trades range-bound.
Worse case25%
Bioprocessing weakness deepens, leading to downward EPS revisions and further multiple compression.
If you hold it
Hold unless bioprocessing segment revenue declines further >5% sequentially next quarter. trim 10% if stock rallies above $200 without order recovery.
If you are watching
Add only if next-quarter guidance is reiterated or raised. avoid if guidance is cut or geopolitical risk escalates.
Scenario odds are a judgement, not measured.